The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Radioligand Therapy Market Evolve From 2026 To 2030?
The radioligand therapy market has experienced substantial expansion in recent years. Forecasts indicate that its valuation will rise from $6.63 billion in 2025 to $7.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this historical growth include the previously limited supply of radioligands, a past reliance on traditional cancer treatments, increasing recognition of the advantages of targeted therapies, greater integration of nuclear medicine practices in hospitals, and the granting of regulatory approvals for initial radioligand therapy drugs.
The radioligand therapy market size is anticipated to experience rapid expansion in the coming years. It is expected to reach $10.72 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.0%. This projected growth during the forecast period can be attributed to the development of novel alpha and beta emitters, the expansion of combined emission therapies, integration with precision oncology, an increase in clinical trials for neurological and cardiovascular applications, and rising investment in home care and outpatient radioligand therapy services. Key trends for the forecast period include the increasing adoption of targeted radioligand therapy in oncology, the expansion of alpha and beta emitter-based therapies, the integration of radioligand therapy with personalized medicine approaches, the growth of hospital and research institution-based radioligand therapy programs, and a rising focus on minimizing side effects and enhancing patient outcomes.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp
What Drivers Are Influencing The Radioligand Therapy Market?
The rising occurrence of cancer is projected to propel the expansion of the radioligand therapy market going forward. Cancer is characterized by the uncontrolled proliferation of abnormal cells that can invade surrounding tissues and spread throughout the body. The increase in cancer incidence is attributed to long-term exposure to environmental pollutants, which damage DNA, disrupt cell function, and promote abnormal cell growth. Radioligand therapy treats cancer by directing radiation to tumor cells through ligands that bind to specific receptors, thereby minimizing harm to healthy tissues and destroying cancer cells internally. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Consequently, the increasing cancer incidence is driving the growth of the radioligand therapy market.
Which Segment Areas Are Covered In The Radioligand Therapy Market Analysis?
The radioligand therapy market covered in this report is segmented –
1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions
2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets
3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral
4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings
Subsegments:
1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)
2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)
3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)
4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)
What Key Developments And Trends Are Impacting The Radioligand Therapy Market?
Leading companies within the radioligand therapy market are focusing on developing sophisticated solutions, such as dedicated radioligand therapy facilities, to boost production efficiency and maintain consistent quality and safety standards in the manufacturing and distribution of precise cancer treatments. Radioligand therapy facilities are specialized centers built to handle and deliver radioactive drugs for targeted cancer treatment, utilizing advanced imaging systems and radiation shielding, all while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. Spanning 70,000 square feet, this facility stands as Novartis’s largest and most advanced site dedicated to RLT, engineered for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling significant increases in supply to meet growing patient demand in the US and Canada.
Which Global Companies Are Actively Competing In The Radioligand Therapy Market?
Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc.
Read the full radioligand therapy market report here:
https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report
Which Regions Are Expected To Experience Rapid Expansion In The Radioligand Therapy Market?
North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Radioligand Therapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp
Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company
Property Management Service Market Report 2026
https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report
Real Estate Rental Market Report 2026
https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report
Financial Accounting Advisory Services Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model